The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

BW-A-868C     7-[1-benzyl-3-[(2-cyclohexyl- 2-hydroxy...

Synonyms: SureCN633483, BW-A868C, AG-D-41099, ACMC-20enf8, BW-A 868C, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

High impact information on BW A 868C

  • Moreover, the potent DP receptor antagonist BW A868C restores LC migration in infected mice [1].
  • Furthermore, they were not shared by the selective DP receptor agonist BW245C and were not prevented by the selective DP receptor antagonist BWA868C, indicating that they were not mediated by DP receptors [2].
  • Neither SQ 29,548 nor BW A868C (TP and DP(1) receptor antagonists, respectively) attenuated the enhancement of G-CSF release evoking any of the prostanoids studied [3].
  • The DP(1) receptor antagonist BWA868C [3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxo-1-(phenylmethyl)-4-imidazolidine-heptanoic acid] enhanced PGD(2)-induced CD203c expression, suggesting that interaction of PGD(2) with DP(1) receptors can limit activation of basophils by this prostaglandin [4].
  • 4. DP receptor class prostanoids (e.g. ZK118182, BW245C, BWA868C, PGD(2)) exhibited high (nanomolar) affinities for [(3)H]-BWA868C binding, while prostanoids selective for EP, FP, IP and TP receptors showed a low (micromolar) affinity [5].

Biological context of BW A 868C

  • 1. BW A868C, a novel compound, behaved as a simple competitive antagonist in a human washed platelet aggregation assay [6].
  • Following exposure to the specific DP receptor antagonist, BW A868C ((+/-)-3-benzyl-5-(6-carboxyhexyl)-1-(2-cyclohexyl-2-hydroxyethylamin o)- hydantoin; 50 micrograms), which had no effect on intraocular pressure by itself, 572C85 (50 micrograms) did not reduce intraocular pressure in rabbits and cats [7].
  • PGD2 induced increases in conjunctival microvascular permeability were inhibited by BW A868C, despite the fact that DP receptor agonists failed to evoke a plasma exudation response [8].
  • The DP antagonist, BWA868C, effectively antagonized the effects of AL-6556 with a high potency (IC50 = 22.8 +/- 3.9 nM; n = 3) [9].

Anatomical context of BW A 868C

  • Effects of a selective DP receptor agonist (BW 245C) and antagonist (BW A868C) on the canine colonic epithelium: an argument for a different DP receptor [10]?
  • PGD(2) also increased eNOS expression on choroids of juveniles, and this effect was blocked by BW A868C [11].
  • The DP receptor antagonist BWA868C competitively antagonized the PGD(2)-induced cAMP accumulation in embryonic bovine tracheal fibroblast cells (pA(2) = 7.83 +/- 0.08) [12].
  • The affinity estimates of BW A868C against BW245C and prostaglandin D2 obtained from dog dorsal nasal vein, major palatine artery and saphenous vein were found to be consistent [13].
  • The concentration and agonist dependence of the action of BW A868C suggests that putative DP receptor agonists relax human myometrium by more than one mechanism [14].

Associations of BW A 868C with other chemical compounds


Gene context of BW A 868C

  • 5. The contractile effects of PGD2 in guinea-pig tracheal strips were resistant to 10 microM BW A868C indicating that they were not mediated through DP-receptors [6].
  • Finally, the DP-receptor antagonist BW A868C did not block the Ca2+ transient response to PGD2, indicating an absence of DP-receptor involvement [20].
  • However, BW A868C effectively antagonized only the mucin secretion mediated by PGD(2) and L-644,698 and not PGE(2) [17].
  • The presence of an AH6809-sensitive, AH23848B- and BW A868C-insensitive mechanism is consistent with the hypothesis that inhibitory EP receptor agonists cause relaxation of human non-pregnant myometrium by an EP2 receptor-mediated process [19].

Analytical, diagnostic and therapeutic context of BW A 868C

  • These effects were mediated via the DP prostanoid receptor; DP receptor agonists BW245C or SQ27986 induced neuronal damage, while the DP receptor antagonist BWA868C was neuroprotective in co-cultures [21].
  • The dilation was converted to constriction by INDO (-54%+/-9%; P<0.05 versus non-IBD) or by BWA868C (PGD2 receptor antagonist) [22].


  1. Role of the parasite-derived prostaglandin D2 in the inhibition of epidermal Langerhans cell migration during schistosomiasis infection. Angeli, V., Faveeuw, C., Roye, O., Fontaine, J., Teissier, E., Capron, A., Wolowczuk, I., Capron, M., Trottein, F. J. Exp. Med. (2001) [Pubmed]
  2. Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Monneret, G., Gravel, S., Diamond, M., Rokach, J., Powell, W.S. Blood (2001) [Pubmed]
  3. Prostanoid receptor expression by human airway smooth muscle cells and regulation of the secretion of granulocyte colony-stimulating factor. Clarke, D.L., Belvisi, M.G., Smith, S.J., Hardaker, E., Yacoub, M.H., Meja, K.K., Newton, R., Slater, D.M., Giembycz, M.A. Am. J. Physiol. Lung Cell Mol. Physiol. (2005) [Pubmed]
  4. Effects of prostaglandin D(2) and 5-lipoxygenase products on the expression of CD203c and CD11b by basophils. Monneret, G., Boumiza, R., Gravel, S., Cossette, C., Bienvenu, J., Rokach, J., Powell, W.S. J. Pharmacol. Exp. Ther. (2005) [Pubmed]
  5. Pharmacology and autoradiography of human DP prostanoid receptors using [(3)H]-BWA868C, a DP receptor-selective antagonist radioligand. Sharif, N.A., Williams, G.W., Davis, T.L. Br. J. Pharmacol. (2000) [Pubmed]
  6. The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist. Giles, H., Leff, P., Bolofo, M.L., Kelly, M.G., Robertson, A.D. Br. J. Pharmacol. (1989) [Pubmed]
  7. Selective prostaglandin D2 receptor stimulation elicits ocular hypotensive effects in rabbits and cats. Matsugi, T., Kageyama, M., Nishimura, K., Giles, H., Shirasawa, E. Eur. J. Pharmacol. (1995) [Pubmed]
  8. Further studies on ocular responses to DP receptor stimulation. Woodward, D.F., Spada, C.S., Hawley, S.B., Williams, L.S., Protzman, C.E., Nieves, A.L. Eur. J. Pharmacol. (1993) [Pubmed]
  9. Molecular pharmacology of the DP/EP2 class prostaglandin AL-6598 and quantitative autoradiographic visualization of DP and EP2 receptor sites in human eyes. Sharif, N.A., Williams, G.W., Crider, J.Y., Xu, S.X., Davis, T.L. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. (2004) [Pubmed]
  10. Effects of a selective DP receptor agonist (BW 245C) and antagonist (BW A868C) on the canine colonic epithelium: an argument for a different DP receptor? Rangachari, P.K., Betti, P.A., Prior, E.T., Roberts, L.J. J. Pharmacol. Exp. Ther. (1995) [Pubmed]
  11. Regulation of endothelial nitric oxide synthase by PGD(2) in the developing choroid. Dumont, I., Hardy, P., Peri, K.G., Hou, X., Molotchnikoff, S., Varma, D.R., Chemtob, S. Am. J. Physiol. Heart Circ. Physiol. (2000) [Pubmed]
  12. Affinities, selectivities, potencies, and intrinsic activities of natural and synthetic prostanoids using endogenous receptors: focus on DP class prostanoids. Sharif, N.A., Crider, J.Y., Xu, S.X., Williams, G.W. J. Pharmacol. Exp. Ther. (2000) [Pubmed]
  13. Effects of BW A868C, a selective prostaglandin DP receptor antagonist, in dog isolated vascular preparations. Liu, Y.J., Jackson, D.M., Blackham, A. Eur. J. Pharmacol. (1996) [Pubmed]
  14. Functional characterization of the prostanoid DP receptor in human myometrium. Fernandes, B., Crankshaw, D. Eur. J. Pharmacol. (1995) [Pubmed]
  15. Molecular characterization of a mouse prostaglandin D receptor and functional expression of the cloned gene. Hirata, M., Kakizuka, A., Aizawa, M., Ushikubi, F., Narumiya, S. Proc. Natl. Acad. Sci. U.S.A. (1994) [Pubmed]
  16. The role of prostanoid TP- and DP-receptors in the bronchoconstrictor effect of inhaled PGD2 in anaesthetized guinea-pigs: effect of the DP-antagonist BW A868C. Hamid-Bloomfield, S., Payne, A.N., Petrovic, A.A., Whittle, B.J. Br. J. Pharmacol. (1990) [Pubmed]
  17. The human prostanoid DP receptor stimulates mucin secretion in LS174T cells. Wright, D.H., Ford-Hutchinson, A.W., Chadee, K., Metters, K.M. Br. J. Pharmacol. (2000) [Pubmed]
  18. Effects of TS-022, a newly developed prostanoid DP(1) receptor agonist, on experimental pruritus, cutaneous barrier disruptions and atopic dermatitis in mice. Arai, I., Takaoka, A., Hashimoto, Y., Honma, Y., Koizumi, C., Futaki, N., Sugimoto, M., Takahashi, N., Inoue, T., Nakanishi, Y., Sakurai, T., Tanami, T., Yagi, M., Ono, N., Nakaike, S. Eur. J. Pharmacol. (2007) [Pubmed]
  19. Inhibitory prostanoid EP receptors in human non-pregnant myometrium. Hillock, C.J., Crankshaw, D.J. Eur. J. Pharmacol. (1999) [Pubmed]
  20. Identification of a single (FP) receptor associated with prostanoid-induced Ca2+ signals in Swiss 3T3 cells. Woodward, D.F., Lawrence, R.A. Biochem. Pharmacol. (1994) [Pubmed]
  21. Prostaglandin D2 mediates neuronal damage by amyloid-beta or prions which activates microglial cells. Bate, C., Kempster, S., Williams, A. Neuropharmacology (2006) [Pubmed]
  22. Novel mechanism of vasodilation in inflammatory bowel disease. Hatoum, O.A., Gauthier, K.M., Binion, D.G., Miura, H., Telford, G., Otterson, M.F., Campbell, W.B., Gutterman, D.D. Arterioscler. Thromb. Vasc. Biol. (2005) [Pubmed]
WikiGenes - Universities